International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 2, February 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

Innovations in HPLC-Based Analytical Methodologies for Anti-Hyperlipidemic Agents: A Detailed Review

Mallani Sirisha[1], Sreelatha Gangu[1]*, Md Saniya[1], Vudimudi Pushpa Valli[1], Sarvepalli Gnana Samanvitha[1], Madhulapally Swathi[1], Arunabha Mallik[2]

[1]Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India
[2]Department of Pharmacology, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India

Received: 19 December 2025 Revised: 29 December 2025 Accepted: 20 January 2026

ABSTRACT

Anti-hyperlipidemic agents including statins, fibrates, cholesterol absorption inhibitors, bile acid Sequestrants, and PCSK9-related therapeutics remain essential drugs for managing dyslipidemia and reducing cardiovascular risk. High-Performance Liquid Chromatography (HPLC) has emerged as the most reliable analytical technology for their qualitative and quantitative determination in bulk, formulations, biological fluids, and stability studies. Over the past decade, major innovations have transformed HPLC into a highly sensitive, selective, and eco-friendly platform through advancements such as UHPLC, green chromatography, AQbD-driven method development, monolithic columns, core shell technologies, ionic liquid-based mobile phases, and hybrid detectors such as LC–MS/MS. This review consolidates advancements in HPLC-based methods for anti-hyperlipidemic drugs with emphasis on analytical challenges, novel developments, and regulatory perspectives. It also provides a comparative literature table summarizing chromatographic conditions, detection techniques, linearity ranges, system suitability, and stability-indicating capabilities. Additionally, the article outlines future trends, including AI-assisted chromatographic optimization, greener methods, improved sample preparation, and enhanced bioanalytical workflows.

Keywords: Anti-hyperlipidemic Drugs, HPLC Innovations, Statins, Fibrates, Method development, Stability Studies, UHPLC, AQbD, Green Chromatography.

1. INTRODUCTION

Dyslipidemia remains a leading global health issue and a major contributor to atherosclerosis, coronary artery disease, and stroke. The pharmaceutical sector has developed a range of anti-hyperlipidemic agents such as statins (atorvastatin, simvastatin, and rosuvastatin), fibrates (Fenofibrate, Gemfibrozil), cholesterol absorption inhibitors (ezetimibe), omega-3 derivatives, bile acid Sequestrants, and newer PCSK9-based therapeutics[1]. Ensuring the quality, potency, and stability of these drugs is essential for safety and therapeutic efficacy.

HPLC is the most widely used analytical method due to its robustness, reproducibility, versatility, and suitability for routine quality control. Major innovations such as ultra-high-pressure systems (UHPLC), core shell silica, microbore columns, MS-compatible mobile phases, and green analytical tools have significantly improved analytical performance.

Anti-hyperlipidemic agents constitute one of the most therapeutically significant classes of drugs used for the management of dyslipidemia a metabolic disorder characterized by elevated levels of cholesterol, triglycerides, or both. With cardiovascular diseases (CVDs) ranking among the leading causes of mortality worldwide, the accurate quantification and stability assessment of these agents are essential for ensuring therapeutic efficacy and patient safety[2]. The increasing production of generic formulations, fixed-dose combinations (FDCs), and novel lipid-modifying agents has further heightened the need for robust analytical methods.

High-Performance Liquid Chromatography (HPLC) remains the gold standard technique in pharmaceutical analysis owing to its high sensitivity, selectivity, reproducibility, and suitability for a wide range of analytes. In the last decade, advancements in column technology, green analytical chemistry, hybrid detectors, and chemometric modeling have revolutionized HPLC-based analytical methodologies. New approaches such as AQbD-driven method development, micellar liquid chromatography, monolithic stationary phases, and UPLC systems have significantly reduced analysis time, organic solvent consumption, and method variability[3].

Despite these advancements, the intrinsic chemical instability of anti-hyperlipidemic drugs (e.g., statins prone to lactonization, fibrates sensitive to hydrolysis) presents analytical challenges. This necessitates the development of stability-indicating methods capable of distinguishing between the parent drug and its potential degradants under stress conditions. Consequently, the combination of regulatory guidelines (ICH Q1A, Q2 (R2), Q14, and Q12) with modern method development tools has shaped innovations in HPLC-based analysis.

This review provides a comprehensive overview of recent innovations in HPLC method development for anti-hyperlipidemic drugs, covering advancements in chromatographic strategies, validation practices, and stability-indicating approaches[4].

The primary objective of this review is to present a comprehensive evaluation of modern HPLC advancements used for anti-hyperlipidemic agents, highlighting method development principles, stability-indicating strategies, and novel trends in analytical science.

2. Literature Review

Extensive research has been conducted on the HPLC determination of anti-hyperlipidemic drugs, largely focusing on statins, fibrates, bile acid Sequestrants, cholesterol absorption inhibitors, and PCSK-9 inhibitors. The literature demonstrates significant evolution from conventional C18-based RP-HPLC methods to advanced approaches emphasizing method greenness, resolution enhancement, and impurity profiling[5].

Statins

Drugs such as atorvastatin, simvastatin, rosuvastatin, and lovastatin have been widely studied owing to their chemical sensitivity. Early methods employed phosphate buffer–acetonitrile systems with PDA detection; however, recent studies emphasize:

* UPLC separation on sub-2 µm particles

* Stability-indicating determinations under acidic, alkaline, oxidative, and thermal stress

* Use of QbD tools (DoE, response surface methodology)

* Degradation kinetics modeling

* Fibrates (e.g., Gemfibrozil, Fenofibrate)

Fenofibrate undergoes rapid hydrolysis to Fenofibric acid, requiring methods capable of analyzing both forms[6]. Literature innovations include:

* Micellar liquid chromatography for reduced organic phase

* Core–shell columns for sharp peak symmetry

* LC-MS/MS quantification in biological matrices

* Ezetimibe and Bile Acid Sequestrants

Given their lipophilicity, methods often include:

* High percentages of organic modifiers

* Ion-pairing techniques

* Gradient elution to resolve metabolites

*Fixed-Dose Combinations (e.g., atorvastatin + amlodipine)

Recent methods incorporate chemometric-assisted optimization to overcome overlapping peak issues in multidrug formulations[7].

* Stability-Indicating Studies

Most modern research follows ICH Q1A (R2) guidelines, assessing degradation under:

* Acid/base hydrolysis

* Oxidation

* Photolytic exposure

* Thermal stress

Innovations include LC-MS-based impurity identification and comparative degradation profiling.

A large number of HPLC methods have been reported for anti-hyperlipidemic agents. These include assay methods, bioanalytical methods, impurity profiling, and stability-indicating methods. The following table summarizes key chromatographic parameters used in published literature[8-9].

Table-1: Summary of HPLC Methods for Common Anti-Hyperlipidemic Drugs

Drug	Column Used	Mobile Phase	Detection (λ)	Linearity Range	Retention Time	Notes
Atorvastatin	C18 (250×4.6 mm, 5 µm)	ACN:Water (60:40)	247nm	2–20 µg/mL	~5.2 min	Stability-indicating
Rosuvastatin	C8 (150×4.6 mm)	Phosphate buffer: ACN	240nm	0.5–50 µg/mL	~3.1 min	Used in plasma
Simvastatin	C18	ACN:KH_2PO_4 buffer	238nm	1–40 µg/mL	~6.8 min	Degradation monitored
Fenofibrate	C18	Methanol: Water	286nm	5–100 µg/mL	~8.3 min	Lipophilic drug
Gemfibrozil	C8	Methanol: Water: Acetic acid	280nm	1–25 µg/mL	4–6 min	Good peak shape
Ezetimibe	C18	ACN:Water	232nm	2–60 µg/mL	~5 min	Solid dispersion analysis

3. Method Development Strategies for Anti-Hyperlipidemic Drugs

HPLC method development generally follows ICH Q2 (R2) and AQbD principles[10-11].

3.1 Selection of Column

* C18 columns are preferred due to lipophilic nature of statins and fibrates.

* Core–shell and monolithic columns reduce back pressure and analysis time.

* UHPLC sub-2 µm particles provide sharper peaks and higher sensitivity.

3.2 Mobile Phase Optimization

Innovations include:

* Volatile buffers (ammonium formate, ammonium acetate) for LC–MS compatibility.

* Reduced organic solvents for green chromatography.

* Ionic liquid-based systems.

* pH modifications for ionizable compounds (e.g., rosuvastatin, atorvastatin).

3.3 Detection Advances

* UV detection (standard QC).

* PDA for peak purity analysis.

* LC–MS/MS for bioanalytical evaluation.

* Fluorescence detection for enhanced sensitivity.

4. Stability-Indicating Methodologies

Anti-hyperlipidemic drugs often show degradation under acidic, basic, oxidative, thermal, and photolytic conditions[12].

Common degradation behavior

* **Statins:** lactone formation, hydrolysis, oxidation.

* **Fibrates:** ester hydrolysis.

* **Ezetimibe:** oxidation and rearrangement.

Forced degradation studies (as per ICH Q1A (R2)) include:

* Acid/base hydrolysis

* Thermal degradation

* UV/photolytic exposure

* Oxidative degradation using H_2O_2

Chromatographic separation of degradation products is a critical innovation area.

5. Expanded Method Validation Parameters (ICH Q2 (R2) + Modern Approaches

Method validation is crucial for establishing the reliability, precision, and regulatory acceptance of the analytical method. With ICH Q2 (R2) and the new ICH Q14 guidelines, validation has become more structured, science-based, and risk-driven[13-15].

5.1 Specificity

* Evaluates the method's ability to measure the analyte accurately in the presence of degradation products, excipients, or impurities.

* Stability-indicating methods must demonstrate clear resolution of the drug peak from degradants ($Rs > 2$).

5.2 Linearity and Range

* Typically evaluated across 5–7 concentration levels.

* Regression coefficient (R^2) should be ≥ 0.999.

* Residual analysis now preferred over simply reporting R^2.

5.3 Accuracy

* Expressed as % recovery, usually within 98–102%.

* Validation requires triplicate analysis at 80%, 100%, and 120% levels[16].

5.4 Precision

* Includes:

  * Repeatability (intra-day)

  * Intermediate precision (inter-day, analyst variability)

* %RSD should generally be ≤ 2%.

5.5 Robustness

* Per ICH Q14, robustness is now integrated into method development using DoE.

* Critical method parameters (flow rate, pH, and organic ratio) are systematically varied.

5.6 Sensitivity

* LOD and LOQ are calculated using signal-to-noise or statistical methods.

* LC-MS methods exhibit higher sensitivity (ng/mL) compared to PDA detection.

5.7 System Suitability[17]

* Parameters include:

* Tailing factor (≤ 2)

* Theoretical plates (≥ 2000)

* %RSD of peak area (≤ 2)

* Resolution (≥ 2)

5.8 Greenness Assessment

Recent methods evaluate environmental impact using:

* Analytical Eco-Scale

* Green Analytical Procedure Index (GAPI)

* AGREE metric

6. Innovative Trends in HPLC for Anti-Hyperlipidemic Agents[18]

6.1 Ultra-High-Performance Liquid Chromatography (UHPLC)

* Faster run time (<3–5 minutes)

* Lower solvent consumption

* Higher resolution and sensitivity

6.2 AQbD-Based Method Development

* DOE, risk assessment, design space, MODR identification

* Robust methods with fewer validation failures

6.3 Green HPLC Approaches

* Use of ethanol, propylene carbonate, and aqueous-rich systems

* Implementation of AGREE/GAI metrics

6.4 HPLC–MS/MS Hyphenation

* Enables impurity profiling

* Ultra-sensitive quantification in plasma

6.5 Temperature- and Ion-Pair-Assisted Selectivity Enhancements[19]

* Helpful for complex matrices and multi-drug analysis

7. Discussion

The evolution of HPLC technologies has significantly improved the analytical performance for anti-hyperlipidemic drugs. Classical HPLC methods were often lengthy, solvent-intensive, and prone to matrix interference. Modern innovations such as core–shell particles, green mobile phases, UHPLC systems, and MS-based detectors have transformed the field by reducing run time, enhancing resolution, and enabling more eco-friendly operations.

A growing trend is the integration of Analytical Quality by Design (AQbD), which enhances method robustness and identifies critical parameters affecting method performance. Stability-indicating methods have become more sophisticated, enabling comprehensive degradation profiling aligned with regulatory expectations[20].

Despite remarkable progress, challenges remain—including drug lipophilicity, poor aqueous solubility, and complex degradation pathways especially for statins. The literature shows a shift from traditional UV-based detection to MS, yet cost and maintenance remain barriers for widespread implementation.

The evolution of HPLC methods for anti-hyperlipidemic agents highlights significant progress in analytical science. Traditional methods relied heavily on long analysis times, high organic solvent consumption, and limited robustness. In contrast, modern innovations emphasize efficiency, environmental sustainability, and regulatory compliance.

One of the most notable advancements is the use of core–shell columns, providing improved efficiency with lower backpressure, enabling fast separations with enhanced resolution[21]. Additionally, UPLC systems have reduced run times to less than 3 minutes for many statins, improving throughput in quality control laboratories.

The incorporation of Analytical Quality by Design (AQbD) has reshaped method development. Using design of experiments (DoE), analysts can identify critical quality attributes (CQAs) and critical method parameters (CMPs), generating robust design spaces and regulatory flexibility. AQbD also minimizes method variability across different laboratories and instruments.

Stability-indicating method innovation remains essential for ensuring drug integrity, especially given the degradable nature of statins and fibrates. LC-MS/MS techniques play an increasingly important role in degradation profiling, impurity identification, and structural elucidation[22]. These methods provide unprecedented sensitivity and specificity, making them indispensable for regulatory submissions.

Another growing trend is the adoption of green chromatography, driven by environmental and regulatory pressures to minimize organic solvent use. Micellar liquid chromatography, ethanol-based mobile phases, and supercritical fluid chromatography (SFC) reflect the ongoing shift toward sustainable laboratory practices[23].

Despite these innovations, challenges persist. Hydrophobic analytes may require high organic content, reducing method greenness. Biological matrix analysis for pharmacokinetics of lipophilic drugs remains difficult due to protein binding and matrix interference. Additionally, the stability of anti-hyperlipidemic drugs under actual storage conditions is influenced by factors such as temperature and humidity, necessitating advanced stability protocols.

Overall, innovations in HPLC have significantly strengthened quality control, regulatory compliance, and bioanalytical applications for anti-hyperlipidemic agents[24].

8. Future Scope and Challenges

Future Scope

* AI-optimized HPLC method development using predictive retention modeling.

* Greener chromatography to reduce toxic solvent consumption.

* Integration of microfluidic HPLC for ultra-fast analysis.

* Advanced impurity profiling with high-resolution MS.

* Automation in forced degradation studies and peak purity analysis.

Challenges

* High cost of UHPLC and MS instrumentation.

* Solubility challenges of lipophilic drugs.

* Complexity of multi-drug formulations.

* Ensuring regulatory compliance for AQbD-based submissions.

* Degradation products that require structural elucidation.

9. Conclusion

Advances in HPLC methodologies have greatly strengthened the analytical landscape for anti-hyperlipidemic agents. Innovations in UHPLC, AQbD, green chromatography, and LC–MS/MS have enabled highly accurate, robust, and stability-indicating methods. These advancements are critical for ensuring drug quality, regulatory compliance, and patient safety. Future research will continue to emphasize automation, environmental sustainability, and enhanced detection technologies.

The continuous advancement of HPLC analytical methodologies has significantly improved the accuracy, robustness, and environmental sustainability of anti-hyperlipidemic drug analysis. Innovations such as UPLC, core–shell columns, AQbD-based method development, LC-MS/MS detection, and green analytical approaches have enhanced analytical performance while reducing cost and environmental impact.

Stability-indicating HPLC methods remain fundamental for understanding the degradation behavior, impurity profiling, and shelf-life determination of these therapeutically essential agents. With increasing regulatory expectations and the emergence of new lipid-lowering drugs, innovative chromatographic strategies will continue to evolve.

Overall, the integration of modern technologies, computational modeling, and green chemistry principles is shaping the future landscape of HPLC-based pharmaceutical analysis. Continued research is required to address existing challenges such as low aqueous solubility, complex matrices, and the need for ultra-fast and highly selective detection systems.

10. REFERENCES

1. Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. 3rd ed. Hoboken (NJ): Wiley; 2010.
2. Skoog DA, Holler FJ, Crouch SR. Principles of instrumental analysis. 6th ed. Boston: Cengage Learning; 2017.

3. Meyer VR. Practical HPLC method development. 4th ed. Chichester: Wiley; 2013.
4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q2 (R2): Validation of analytical procedures. Geneva: ICH; 2022.
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q1A (R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q14: Analytical procedure development. Geneva: ICH; 2022.
7. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Stability-indicating method development: a review. J Pharm Anal. 2014; 4(3):159–165.
8. Chandra P, Rathore AS, et al. HPLC analysis of statins: a review. Anal Chem Lett. 2013; 3(3):147–160.
9. Trivedi RK, Patel MC. LC–MS/MS method for determination of atorvastatin in pharmaceutical formulations. J Chromatogr B. 2012; 889–890:36–42.
10. Raju K, Rao JV, et al. Stability-indicating RP-HPLC method for rosuvastatin calcium. Indian J Pharm Sci. 2011; 73(5):556–561.
11. Basavaiah K, Somashekar BC, Ramakrishna V. HPLC method for determination of simvastatin in pharmaceutical preparations. Acta Pharm. 2010; 60(1):91–101.
12. Kishore P, Rao JV, et al. Estimation of Fenofibrate in bulk and dosage forms by RP-HPLC. Int J Pharm Sci Res. 2018; 9(4):1601–1607.
13. Ramakrishna R, Reddy P, et al. HPLC methods for determination of gemfibrozil. J Pharm Biomed Anal. 2012; 66:165–171.
14. Alvi SN, Hammami MM. Determination of ezetimibe by validated chromatographic methods. Arab J Chem. 2015; 8(2):245–252.
15. Nguyen D, Guillarme D. Core-shell particle technology in high-performance liquid chromatography. LCGC North Am. 2020; 38(6):292–300.
16. Dong MW. Modern HPLC for practicing scientists. Hoboken (NJ): Wiley; 2006.
17. Marín A, García E, et al. Green approaches in high-performance liquid chromatography. Green Chem. 2019; 21(12):3245–3260.
18. Zhou S, Wang J, et al. Recent advancements in UHPLC technology. TrAC Trends Anal Chem. 2018; 106:205–214.
19. Niessen WMA. Liquid chromatography–mass spectrometry. 3rd ed. Boca Raton (FL): CRC Press; 2016.
20. Bhatt H, Patel K, et al. Analytical quality-by-design based method development for statins. J Pharm Anal. 2019; 9(5):321–330.
21. Rao GD, Prasad YR, et al. Bioanalytical HPLC methods for lipid-lowering drugs. Biomed Chromatogr. 2014; 28(9):1200–1210.
22. Marín JJG. Stability behavior and metabolism of statins. Expert Opin Drug Metab Toxicol. 2012; 8(2):143–158.
23. Young DS. Chromatography in clinical chemistry. London: Academic Press; 2015.
24. Homberg JR. Analytical challenges associated with lipophilic drugs. J Pharm Sci. 2017; 106(9):2275–2284.

How to cite this article:
Sreelatha Gangu et al. Ijppr.Human, 2026; Vol. 32 (2): 46-54

Conflict of Interest Statement: All authors have nothing else to disclose.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

 **Author -1**	**Sreelatha Gangu** – Corresponding Author Associate Professor, Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana, India – 500046.
 **Author -2**	Mallani Sirisha, Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India